Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies

Study Overview
=================
Brief Summary
-----------------
This is multicentric, observational, and prospective study.

Detailed Description
-----------------
The project aims to develop a regional platform for innovative disease treatment oncology. In particular, an integrated platform will be created with several complementary skills among them, which have as their common objective to increase knowledge and the possibilities of surgery for certain types of cancer. The actions implemented in this project will be as follows: Improvement of primary and secondary prevention strategies with precocious diagnostic devices; Optimization of therapeutic treatments by custom drawing of the scheme therapeutic; Improved therapeutic efficacy for high social impact resistant neoplasms development of innovative treatments such as personalized therapeutic vaccines and small molecules; Improving patient compliance and quality of life accompanied by less need of hospitalization of the patient himself with consequent decongestion of hospital admissions; Reduction of health costs as a result of early diagnosis and new therapies more effective and less invasive; Increasing regional health and technological attractiveness in a high bio-medical sector social and health impact.

Official Title
-----------------
Fighting Cancer Resistance: Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies

Conditions
-----------------
Biologic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Diagnosis of any of the following diseases: breast cancer; melanoma; hepatocarcinoma; gynecological cancer; colorectal cancer; lung cancer. 2. Signature of the informed consent for the study. 3. Age 18 years 4.Biological material leftover from biopsy or surgery, and the residual to the activities of clinical assistance analysis. 5. No ongoing treatment for oncological diseases at the time of collection. 6. Planned start of systemic anti-neoplastic treatment within 30 days of inclusion in the observational study. Exclusion Criteria: 1. Positive anamnesis of previous neoplasms; 2. Positive anamnesis for synchronous/metachronous oncological diseases other than those foreseen for the recruitment; 3. Immunosuppressive therapy in progress.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sampling of biological material from cancer patients. | Sampling size and type of biomaterials, residues in diagnosis and/or clinical activities care, collected by cancer patients and properly stored will include: - cells and/or tissue fragments during surgical excision (with open approach/ laparoscopic/ robotic) of the tumor or parts of the same tissue | 3 years | 
| Sampling of biological material from cancer patients. | Sampling size and type of biomaterials, residues in diagnosis and/or clinical activities care, collected by cancer patients and properly stored will include:- blood, cell samples, urine/other biological liquids (saliva, excreted, ascites, pleural fluids, etc.) and faeces, | 3 years | 
| Sampling of biological material from cancer patients. | Sampling size and type of biomaterials, residues in diagnosis and/or clinical activities care, collected by cancer patients and properly stored will include:- samples fixed in formalin and included in paraffin (Formalin-fixed paraffin-embedded, FFPE). | 3 years | 
| Identification of biomarkers to be used for the development of early diagnostic systems | The alteration of the levels of biomarkers, measured by the use of analytical techniques based on mass spectrometry, and the correlation of such levels measured against control samples will allow the development and training of advanced statistics models to identify and define the type and the status of the oncological pathology. | 3 years | 
| Monitoring the progress of drug therapies | The identification of biomarkers used to monitor the drug therapie defined as pharmacometabolomics will allow to calibrate finely and optimize the selection of therapeutic protocols allowing to reduce the costs of prescription and assistance, while improving the patient's health. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Realization of a regional Technology platform